Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.

被引：0
|
作者：
Shi, Qian
De Gramont, Aimery
Buyse, Marc E.
Grothey, Axel
Schmoll, Hans-Joachim
Seymour, Matthew T.
Adams, Richard A.
Saltz, Leonard
Goldberg, Richard M.
Punt, Cornelis J. A.
Douillard, Jean-Yves
Hecht, J. Randolph
Hurwitz, Herbert
Diaz-Rubio, Eduardo
Porschen, Rainer
Tebbutt, Niall C.
Fuchs, Charles S.
Souglakos, John
Falcone, Alfredo
Sargent, Daniel J.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Hosp St Antoine, Paris, France
[3] Int Inst Drug Dev, Louvain, Belgium
[4] Univ Halle Wittenberg, D-06108 Halle, Germany
[5] Canc Res UK Clin Ctr, Leeds, W Yorkshire, England
[6] Cardiff Univ, Sch Med, Cardiff CF10 3AX, S Glam, Wales
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[8] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA
[9] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[10] ICO Ctr Rene Gauducheau, St Herblain, France
[11] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[12] Duke Univ, Med Ctr, Durham, NC USA
[13] Hosp Clin San Carlos, Madrid, Spain
[14] Klinikum Bremen Ost, Bremen, Germany
[15] Austin Hlth, Heidelberg, Vic, Australia
[16] Univ Melbourne, Heidelberg, Vic, Australia
[17] Dana Farber Canc Inst, Boston, MA 02115 USA
[18] Univ Crete, Sch Med, Iraklion, Greece
[19] Santa Chiara Hosp, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3533
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer (mCRC)
    Sidhu, R.
    Rong, A.
    Dahlberg, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients
    Sjoquist, Katrin Marie
    Bokemeyer, Carsten
    Renfro, Lindsay A.
    Simes, John
    Tebbutt, Niall C.
    Clarke, Stephen John
    Adams, Richard
    Punt, Cornelis J. A.
    Van Cutsem, Eric
    Douillard, Jean-Yves
    Hecht, J. Randolph
    Heinemann, Volker
    Sougklakos, Ioannis
    Diaz-Rubio, Eduardo
    Porschen, Rainer
    Meyers, Jeffrey P.
    Gonsalves, Wilson I.
    Sargent, Daniel J.
    De Gramont, Aimery
    Zalcberg, John Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Nomograms for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.
    Sjoquist, Katrin Marie
    Renfro, Lindsay A.
    Simes, John
    Tebbutt, Niall C.
    Clarke, Stephen John
    Meyers, Jeffrey P.
    Gonsalves, Wilson I.
    Adams, Richard
    Seymour, Matthew T.
    Saltz, Leonard
    Schmoll, Hans
    Sargent, Daniel J.
    De Gramont, Aimery
    Zalcberg, John Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] PROGRESSION-FREE SURVIVAL (PFS) IS CORRELATED WITH OVERALL SURVIVAL (OS) IN CLINICAL STUDIES OF TARGETED THERAPIES PLUS CHEMOTHERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC)
    Sidhu, Roger
    Rong, Alan
    Dahlberg, Steve
    ANNALS OF ONCOLOGY, 2011, 22 : v120 - v120
  • [5] Circadian robustness as an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC).
    Levi, Francis
    Parganiha, Arti
    Karaboue, Abdoulaye
    Innominato, Pasquale F.
    Giacchetti, Sylvie
    Garufi, Carlo
    Dispersyn, Garance
    Focan, C. N. J.
    Iacobelli, Stefano
    Bjarnason, Georg A.
    Moreau, Thierry
    Dugue, Pierre Antoine
    Waterhouse, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [6] Can overall survival (OS) benefit be predicted from improvements in progression-free survival (PFS) for previously untreated metastatic colorectal cancer (mCRC)?
    Roodhart, Jeanine
    Dave, Kiran
    Dixon, Matthew
    Kurt, Murat
    Pushkarna, Divya
    Pourrahmat, Mir-Masoud
    Fazeli, Mir Sohail
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 222 - 222
  • [7] Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
    Venook, Alan P.
    Niedzwiecki, Donna
    Innocenti, Federico
    Fruth, Briant
    Greene, Claire
    O'Neil, Bert H.
    Shaw, James Edward
    Atkins, James Norman
    Horvath, Laura E.
    Polite, Blase N.
    Meyerhardt, Jeffrey A.
    O'Reilly, Eileen Mary
    Goldberg, Richard M.
    Hochster, Howard S.
    Blanke, Charles David
    Schilsky, Richard L.
    Mayer, Robert J.
    Bertagnolli, Monica M.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] EXPLORING ENDPOINT CORRELATION BETWEEN PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PREVIOUSLY UNTREATED METASTATIC MELANOMA USING PSEUDO INDIVIDUAL PATIENT DATA (IPD)
    Kanters, S.
    Kurt, M.
    Moshyk, A.
    Leung, L.
    VALUE IN HEALTH, 2022, 25 (12) : S20 - S20
  • [9] Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.
    Coart, Elisabeth
    Saad, Everardo D.
    Shi, Qian
    Sommeijer, Dirkje Willemien
    Zalcberg, John Raymond
    Maughan, Tim
    Goldberg, Richard M.
    Schmoll, Hans-Joachim
    Punt, Cornelis J. A.
    Van Cutsem, Eric
    Douillard, Jean-Yves
    Hoff, Paulo Marcelo
    Tebbutt, Niall C.
    Fuchs, Charles S.
    Falcone, Alfredo
    Tournigand, Christophe
    De Gramont, Aimery
    Sargent, Daniel J.
    Burzykowski, Tomasz
    Buyse, Marc E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [10] Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials.
    Oba, Koji
    Paoletto, Xavier
    Bang, Yung-Jue
    Bouche, Olivier
    Ducreux, Michel
    Michiels, Stefan
    Moehler, MarkusH
    Morita, Satoshi
    Ohashi, Yasuo
    Sakamoto, Junichi
    Sasako, Mitsuru
    Shitara, Kohei
    Van Cutsem, Eric
    Buyse, Marc E.
    Burzykowski, Tomasz
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345